Interactive effects of asparagine and aspartate homeostasis with sex and age for the risk of type 2 diabetes risk

Springer Science and Business Media LLC - 2020
Hao Luo1, Xiaofei Feng1, Xilin Yang2, Ruiqin Hou3, Zhong‐Ze Fang4
1Department of Toxicology and Sanitary Chemistry, School of Public Health, Tianjin Medical University, Tianjin 300070, China
2Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China
3Department of Blood Transfusion, Peking University People’s Hospital, Beijing, China
4Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin, China

Tóm tắt

Abstract Background Asparagine and aspartate homeostasis are linked with type 2 diabetes (T2D). This study aimed to explore whether asparagine and aspartate metabolism interacted with sex and age to increase the risk of T2D. Methods From 27 May 2015 to 3 August 2016, we consecutively retrieved 1032 T2D patients and 1522 subjects without T2D from a tertiary care hospital in Liaoning, China. Restricted cubic spline nested in the logistic regression was used to draw odds ratio curves of plasma asparagine to aspartate ratio for T2D by sex and age. Cut-off point was selected where curves went apart, indicating possible interaction. Addictive interactions of asparagine to aspartate ratio with sex or age and secondary interaction with copresence of unfavorable sex and age were further estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S). Results Ratio of asparagine to aspartate > 1.5 was associated with elevated risk of T2D (OR 7.99, 95%CI 5.50 to 11.6), which was enhanced by female gender to 13.6, (95%CI 8.10–22.9) and by > 50 years of age to 28.7 (14.6–56.3), with significant additive interactions. There was a significant secondary-interaction of copresence of female sex and > 50 years of age with high asparagine to aspartate ratio for increased T2D risk with the OR being further increased to 34.4 (20.5–57.5). Conclusions High asparagine to aspartate ratio was associated with markedly increased risk of T2D, which was further amplified by either female gender or > 50 years of age, and especially both.

Từ khóa


Tài liệu tham khảo

Huebschmann AG, Huxley RR, Kohrt WM, et al. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62(10):1761–72.

Li J, Ni J, Wu Y, et al. Sex differences in the prevalence, awareness, treatment, and control of diabetes mellitus among adults aged 45 years and older in rural areas of Northern China: A Cross-Sectional. Population-Based Study. Frontiers in endocrinology. 2019;10:147.

Choi YJ, Kim HC, Kim HM, et al. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes care. 2009;32(11):2016–20.

Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet. 369(9563):0–756.

Jeffery SC, Hosking J, Jeffery AN, et al. Insulin resistance is higher in prepubertal girls but switches to become higher in boys at age 16: A Cohort Study (EarlyBird 57). Pediatric diabetes. 2018;19(2):223–30.

Gurka MJ, Vishnu A, Santen RJ, et al. Progression of metabolic syndrome severity during the menopausal transition. J Am Heart Assoc. 2016;5(8):e003609.

Sattar N. Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best practice & research Clinical endocrinology & metabolism. 2013;27(4):501–7.

Logue J, Walker JJ, Colhoun HM, et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia. 2011;54(12):3003–6.

Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–60.

Richards NGJ, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem. 2006;75(1):629.

Milman HA, Cooney DA. The distribution of l-asparagine synthetase in the principal organs of several mammalian and avian species. Biochem J. 1974;142(1):27–35.

Zuo S, Zhang T, Jiang B, et al. Recent research progress on microbial L-asparaginases. Appl Microbiol Biotechnol. 2015;99(3):1069–79.

Iida S, Kamiya H, Nakaya A, et al. Reduced plasma glucose by asparagine synthetase knockdown in the mouse liver. Biol Pharm Bull. 2013;36(12):2009–11.

Wang X, Liu Y, Wang S, et al. Asparagine reduces the mRNA expression of muscle atrophy markers via regulating protein kinase B (Akt), AMP-activated protein kinase alpha, toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling in weaning piglets after lipopolysaccharide challenge. Br J Nutr. 2016;116(7):1188–98.

Krall AS, Xu S, Graeber TG, et al. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun. 2016;7:11457.

Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125(18):2222–31.

Jacob S, Nodzenski M, Reisetter AC, et al. Targeted metabolomics demonstrates distinct and overlapping maternal metabolites associated with BMI, glucose, and insulin sensitivity during pregnancy across four ancestry groups. Diabetes care. 2017;40(7):911–9.

Meyer MR, Clegg DJ, Prossnitz ER, et al. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf). 2011;203(1):259–69.

Alonso C, Fernandez-Ramos D, Varela-Rey M, et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology. 2017;152(6):1449–61.e7.

Alayev A, Salamon RS, Berger SM, et al. mTORC1 directly phosphorylates and activates ERalpha upon estrogen stimulation. Oncogene. 2016;35(27):3535–43.

Li J, Cao YF, Sun XY, et al. Plasma tyrosine and its interaction with low high-density lipoprotein cholesterol and the risk of type 2 diabetes mellitus in Chinese. J Diabetes Investig. 2019;10(2):491–8.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.

Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17(Suppl):1–36.

Lam DW, LeRoith D. Metabolic Syndrome. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

Wang Q, Sun T, Cao Y, et al. A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. OncoTargets and therapy. 2016;9:1389–98.

May M. In: Harrell Jr FE, editor. Regression Modelling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001. p. 568, $79.95. ISBN 0-387-95232-2. International Journal of Epidemiology. 2002;31(3).

Andersson T, Alfredsson L, Källberg H, et al. Calculating measures of biological interaction. Eur J Epidemiol. 2005;20(7):575–9.

Rebholz CM, Yu B, Zheng Z, et al. Serum metabolomic profile of incident diabetes. Diabetologia. 2018;61(5):1046–54.

Ottosson F, Smith E, Melander O, et al. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. J Clin Endocrinol Metab. 2018;103(8):3060–9.

Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab. 2013;304(8):E789–99.

Wang X, Liu Y, Wang S, et al. Asparagine reduces the mRNA expression of muscle atrophy markers via regulating protein kinase B (Akt), AMP-activated protein kinase α, toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling in weaning piglets after lipopolysaccharide challenge. Br J Nutr. 2016;116(7):1188–98.

Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960–76.

Brown LM, Clegg DJ. Central effects of estradiol in the regulation of food intake, body weight, and adiposity. J Steroid Biochem Mol Biol. 2010;122(1-3):65–73.

Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Jama. 2013;310(13):1353–68.

D'Eon TM, Souza SC, Aronovitz M, et al. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem. 2005;280(43):35983–91.

Cederroth CR, Vinciguerra M, Gjinovci A, et al. Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes. 2008;57(5):1176–85.

Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocr Rev. 2017;38(3):173–88.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả